← Back to Screener
BioVie, Inc. Common Stock (BIVI)
Price$1.46
Favorite Metrics
Price vs S&P 500 (26W)-32.41%
Price vs S&P 500 (4W)-5.82%
Market Capitalization$10.64M
All Metrics
Book Value / Share (Quarterly)$2.55
P/TBV (Annual)0.91x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.90
Price vs S&P 500 (YTD)18.91%
EPS (TTM)$-5.13
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-5.13
EPS (Annual)$-11.87
ROI (Annual)-92.27%
Cash / Share (Quarterly)$2.72
ROA (Last FY)-81.36%
EBITD / Share (TTM)$-4.27
ROE (5Y Avg)-783.38%
Cash Flow / Share (Annual)$-9.94
P/B Ratio0.55x
P/B Ratio (Quarterly)0.45x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-8.70x
ROA (TTM)-72.99%
EPS Incl Extra (Annual)$-11.87
Current Ratio (Annual)9.10x
Quick Ratio (Quarterly)6.90x
3-Month Avg Trading Volume0.09M
52-Week Price Return-83.70%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.55
52-Week High$13.20
EPS Excl Extra (Annual)$-11.87
Tangible BV CAGR (5Y)100.59%
26-Week Price Return-28.43%
Quick Ratio (Annual)8.64x
13-Week Price Return11.90%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.25x
Enterprise Value$-9.904
Book Value / Share Growth (5Y)80.07%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$9.17
3-Month Return Std Dev75.40%
Net Income / Employee (TTM)$-1
ROE (Last FY)-92.27%
Net Interest Coverage (Annual)-32.25x
EPS Basic Excl Extra (Annual)$-11.87
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.13
ROI (TTM)-82.03%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$9.84
Price vs S&P 500 (52W)-113.53%
Year-to-Date Return21.55%
5-Day Price Return-2.08%
EPS Normalized (Annual)$-11.87
ROA (5Y Avg)-526.91%
Month-to-Date Return0.71%
Cash Flow / Share (TTM)$-1.44
EBITD / Share (Annual)$-12.07
LT Debt / Equity (Annual)0.34x
ROI (5Y Avg)-631.46%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-5.13
P/TBV (Quarterly)0.46x
P/B Ratio (Annual)0.90x
Book Value / Share (Annual)$9.93
Price vs S&P 500 (13W)11.22%
Beta0.63x
Revenue / Share (TTM)$0.00
ROE (TTM)-82.03%
52-Week Low$1.06
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BIVIBioVie, Inc. Common Stock | — | — | — | — | $1.46 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
BioVie Inc. is a clinical-stage biopharmaceutical company developing therapies for neurological and liver diseases. Its lead program, NE3107, is advancing through Phase 3 clinical trials for mild to moderate Alzheimer's disease. BIV201 targets life-threatening complications of advanced liver disease, including cirrhosis from hepatitis, non-alcoholic fatty liver disease, and alcohol-related liver injury.